Trial document




This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00003762

Trial Description

start of 1:1-Block title

Title

Phase II/III Study for Remission Induction With Bortezomib (Vel), Cyclophosphamide (C) and Dexamethasone (D) in Patients <= 60 Years With Untreated Multiple Myeloma and Planned High Dose Chemotherapy: (VelCD)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The purpose of this clinical study is to investigate induction therapy for remission with
bortezomib, cyclophosphamide and dexamethasone in patients aged 60 years and younger with
multiple myeloma planned for high-dose chemotherapy with stem cell transplantation.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Today high dose chemotherapy (HD-CT) with stem cell support is considered the standard for
younger patients with multiple myeloma. The standard protocol for induction therapy before
HD-CT is a combination therapy consisting of vincristine, adriamycin and dexamethasone. 40%
of the patients do not respond to conventional induction therapy. With the combination of
bortezomib and cyclophosphamide, a potent cytotoxic substance already in use against
multiple myeloma, an increased efficacy is expected. In this prospective, open-label,
single arm, multi-center study, induction therapy for remission with bortezomib,
cyclophosphamide and dexamethasone in patients aged 60 years and younger with multiple
myeloma planned for high-dose chemotherapy with stem cell transplantation is investigated.
In the first part an evaluation of an optimal dose of cyclophosphamide if combined with a
fixed bortezomib and dexamethasone dose is done and in the second part, efficacy and
tolerance of the assessed dose is evaluated. Primary outcome of the second part is response
prior to high dose chemotherapy. The first part (dose definition) has already been
completed.On the days patients receive bortezomib, vital signs and blood tests and, at the
first day of each cycle, a physical examination will be performed. Adverse events are to be
documented and reported during the study in accordance with ICH-GCP guidelines. 400 male and
female patients with untreated Multiple Myeloma are to be included in this study. In the
first part of the study, the number of patients was restricted to 30. Thus, approximately
370 patients were to be included in the second part. Bortezomib 1,3 mg/m2 by intravenous
bolus on Day 1, 4, 8, and 11 for a maximum of 3 cycles. One cycle consists of 21 days.
Cyclophosphamide 900mg as intravenous infusion on Day 1 of each cycle. Dexamethasone 40 mg
on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003762
  •   2012/05/02
  •   2009/01/23
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT00833560  (ClinicalTrials.gov)
  •   CR005242  (Janssen-Cilag G.m.b.H)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Multiple Myeloma
  •   Remission Induction
  •   Stem Cell Transplantation
  •   C90.0 -  Multiple myeloma
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Cyclophosphamide (Cy)
  •   Drug: Bortezomib (Btz)
  •   Drug: Dexamethasone (D)
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   II-III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Efficacy (Response); time frame: efficacy of response after every one of three cycles

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Tolerability and comparison of response rates in different cytogenetic risk groups; time frame: efficacy of response after every one of three cycles

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  • [---]*
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2006/03/31
  •   401
  •   [---]*
  •   [---]*
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   60   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Multiple Myeloma stage II/III Durie and Salmon

- Patients without preceding cytostatic treatment, however, pretreatment with
dexamethasone is allowed

- Written informed consent

- Female patients have to be postmenopausal or surgically sterilized or willing to use
an acceptable method of birth control (i.e.1 hormonal contraceptives, intrauterine
device, diaphragm with spermicide, total abstinence or a vasectomised partner) during
and 6 months after the treatment, pregnancy test has to be negative

- Male patients have to use an acceptable method of birth control during and 6 months
after the treatment

- males should be offered sperm cryoconservation

- Karnofsky performance status >= 60%

- AST and ALT < 2.5 x the upper limit of normal (ULN)

- Bilirubin < 2.5 x the upper limit of normal (ULN)

- Adequate haematological parameters: leucocytes >= 3.0 x 109/l, neutrophils >= 1.5 x
109/l, platelets >= 75 x 109/l

- Creatinin < 2 x the upper limit of normal (ULN)

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Non-secretory multiple myeloma

- known allergy or hypersensitivity to bortezomib, bor, mannitol, cyclophosphamide

- Estimated life expectancy less than 3 months

- History of cancer (except basal cell carcinoma) in the last 5 years

- Patients with history of peripheral neuropathy CTC grade >= 2

- Other severe illnesses that could potentially interfere with the completion of
treatment according to this protocol: a. Insufficient liver or renal function,
clinically relevant lung disease or gastrointestinal diseases, b. New York Heart
Association (NYHA) > Class II heart failure, myocardial infarction within 6 months of
enrollment, uncontrolled angina, severe uncontrolled ventricular arrhythmias (Lown
IVB), electrocardiographic evidence of acute ischemia or active conduction system
abnormalities, cardiac amyloidosis, c. Active systemic infection requiring treatment,
d. Poorly controlled hypertension or vascular disease. Diabetes mellitus, or other
serious endocrine or metabolic diseases

- Patients with hypotension (defined as RRsys sitting <= 100 mmHg and/or RRdia sitting
<= 60 mmHg

- HIV positive patients

- Patients with active hepatitis B and/or C

- Pregnant or breast-feeding female patients

- Insufficient compliance, foreseeable follow-up problems, psychiatric diseases, known
abuse of alcohol or drugs, legal incompetence

- Participation in another trial either parallel to this trial or within the last 30
days before enrollment into this trial

- except drug studies for relapse in the observation period.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Janssen-Cilag G.m.b.H
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Janssen-Cilag G.m.b.H
    • Janssen-Cilag G.m.b.H. Clinical Trial 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Janssen-Cilag G.m.b.H
    • Janssen-Cilag G.m.b.H. Clinical Trial 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2009/06/01
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   45
  •   2013/10/30
* This entry means the parameter is not applicable or has not been set.